Lyell CEO Lynn Seely appointed interim CFO; Veronica Sanchez Bulis named principal accounting officer

Lyell Immunopharma, Inc.

Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.
Veronica Sanchez Bulis, VP Corporate Controller since Aug 2021, appointed principal accounting officer.
Bulis previously held senior finance roles at Sangamo Therapeutics and Core-Mark International; began career at EY and Deloitte.
No departure or replacement of a named executive officer was disclosed; changes effective immediately.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.